Dr. Shitara on Analyzing the Effects of Prior Therapy on TAS-102 in Gastric/GEJ Cancer

Video

Kohei Shitara, MD, discusses the rationale to analyze the effects of prior therapy on outcomes with TAS-102 in patients with metastatic gastric/gastroesophageal junction cancer.

Kohei Shitara, MD, chief, Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan, discusses the rationale to analyze the effects of prior therapy on outcomes with TAS-102 (trifluridine/tipiracil; Lonsurf) in patients with metastatic gastric/gastroesophageal junction (GEJ) cancer.

During the 2021 Gastrointestinal Cancers Symposium, findings from an analysis of the phase 3 TAGS trial were presented in a virtual poster. The results showed that TAS-102, administered as third- or later-line treatment in patients with metastatic gastric/GEJ cancer, improved survival outcomes compared with placebo irrespective of prior therapy.

TAS-102 is an oral combination that was approved in February 2019 for the treatment of patients with metastatic gastric/GEJ cancer who have received at least 2 prior lines of chemotherapy based on data from the TAGS trial. The regimen is also approved in the European Union and Japan for use in this patient population, concludes Shitara.

Related Videos
Pashtoon Murtaza Kasi, MD, MS
Shannon N. Westin, MD, MPH, FACOG, director, Early Drug Development, clinical medical director, professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, codirector, Ovarian Cancer Moonshot Program, The University of Texas MD Anderson Cancer Center
Hans Lee, MD, associate professor, director, Multiple Myeloma Clinical Research, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Video 6 - "Patient Case 2: A 62-Year-Old Woman with Metastatic Rectal Cancer"
Video 5 - "Adverse Events Associated With TAS-102 Plus Bevacizumab in CRC"
Michael J. Overman, MD
Jason Efstathiou, MD, DPhil
Amin Nassar, MD
Haeseong Park, MD, MPH
Matthew P. Goetz, MD